About pluri inc - PLUR
Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.
PLUR At a Glance
Pluri, Inc.
MATAM Advanced Technology Park
Haifa, Haifa 3508409
| Phone | 972-74-710-8600 | Revenue | 1.34M | |
| Industry | Biotechnology | Net Income | -22,583,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 309.816% | |
| Fiscal Year-end | 06 / 2026 | Employees | 127 | |
| View SEC Filings |
PLUR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 23.479 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.304 |
| Enterprise Value to Sales | 37.695 |
| Total Debt to Enterprise Value | 0.676 |
PLUR Efficiency
| Revenue/Employee | 10,519.685 |
| Income Per Employee | -177,818.898 |
| Receivables Turnover | 1.85 |
| Total Asset Turnover | 0.034 |
PLUR Liquidity
| Current Ratio | 0.683 |
| Quick Ratio | 0.683 |
| Cash Ratio | 0.651 |
PLUR Profitability
| Gross Margin | 25.299 |
| Operating Margin | -1,659.88 |
| Pretax Margin | -1,740.644 |
| Net Margin | -1,690.344 |
| Return on Assets | -57.75 |
| Return on Equity | N/A |
| Return on Total Capital | -83.001 |
| Return on Invested Capital | -158.985 |
PLUR Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 125.147 |
| Total Debt to Total Assets | 88.023 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 22.427 |